EVAR Update: Companies Target Complex Anatomies With Innovative Solutions
As endovascular aortic repair (EVAR) becomes a mainstream procedure, companies are racing to develop products that can treat patients with more challenging anatomy. As the space bubbles with ongoing trials and new-product launches, newer companies hope to make their mark in a space dominated by the established market leaders Medtronic PLC, Cook Medical Inc. and WL Gore & Associates.
You may also be interested in...
Although thoracic endovascular aortic repair (TEVAR) is now routine for lesions like dissection of the descending aorta, the Big Three aortic endovascular companies are developing devices for the more technically challenging proximal and distal portions of the thoracic aorta while physicians refine TEVAR in the descending aorta. Insiders say endovascular techniques are overcoming limitations and physicians will soon be able to treat the entire aorta, from the aortic valve to the bifurcation.
The endovascular abdominal aortic aneurysm repair (EVAR) market is one of the brightest growth opportunities in the medical device arena today. As a result, the competitive landscape is heating up as several new entrants stake their claim for a share of this $1+ billion opportunity.
In this week's podcast edition of Five Must-Know Things: GSK’s R&D head departs; Bayer’s pharma R&D chief prioritizes assets; new US launches in atopic dermatitis; is Abivax an M&A target; and China’s gene therapy developers rush to the clinic.